Sera Prognostics Inc (SERA) Stock Up 18.67%: Is It a Good Investment?

A share price of Sera Prognostics Inc [SERA] is currently trading at $1.78, up 18.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SERA shares have gain 11.25% over the last week, with a monthly amount drifted -24.26%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Sera Prognostics Inc [NASDAQ: SERA] stock has seen the most recent analyst activity on March 30, 2022, when Citigroup downgraded its rating to a Neutral and also revised its price target to $4 from $18. Previously, Oppenheimer started tracking the stock with Outperform rating on November 19, 2021, and set its price target to $19.

Sera Prognostics Inc experienced fluctuations in its stock price throughout the past year between $1.37 and $9.13. Sera Prognostics Inc [NASDAQ: SERA] shares were valued at $1.78 at the most recent close of the market.

Analyzing the SERA fundamentals

Gross Profit Margin for this corporation currently stands at 0.09% with Operating Profit Margin at -319.9%, Pretax Profit Margin comes in at -286.85%, and Net Profit Margin reading is -286.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.51 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Sera Prognostics Inc [NASDAQ:SERA] is 2.02. As well, the Quick Ratio is 2.02, while the Cash Ratio is 0.22. Considering the valuation of this stock, the price to sales ratio is 558.82, the price to book ratio is 0.71.

Transactions by insiders

Recent insider trading involved Jackson Benjamin, General Counsel, that happened on Jun 10 ’25 when 965.0 shares were sold. Chief Scientific Officer, Boniface John J. completed a deal on Jun 10 ’25 to sell 1439.0 shares. Meanwhile, Officer Lindgardt Zhenya bought 3344.0 shares on Jun 10 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.